medigraphic.com
ISSN 2007-6800 (Print)

2016, Number 2

<< Back

Rev Mex Traspl 2016; 5 (2)

In memoriam of one of the greatest in transplantation: «Dr. Paul I. Terasaki» (September 10, 1929-January 25, 2016)

Marino-Vázquez LA, Alberú J, Morales-Buenrostro LE

Language: Spanish
References: 36
Page: 79-87
PDF size: 328.87 Kb.


ABSTRACT

All transplant community received with great sadness the news of the death of Dr. Paul Ichiro Terasaki, which occurred on January 25, 2016, at his home in Beverly Hills, at 86 years old. Dr. Terasaki is one of the most recognized figures in the area of transplantation, since it was one of the pioneers of the study of HLA in transplantation, surgery professor for 50 years at UCLA, and founder of the American Society of Transplantation. The four most important innovations in the Transplantation area according to his own testimony, were: 1) Microlymphocytotoxicity test (microtest) for HLA typing and antibody detection. 2) Having achieved the exchange of organs between different centers. 3) The development of beads coated with HLA antigens to detect antibodies using Luminex® technology. 4) The creation of the company «One Lambda», so far the most important worldwide in the production of inputs for histocompatibility laboratories. We can say that he died with the conviction that the time proved him right when it was demosnstrated that anti-HLA antibodies were the leading cause of graft loss, a theory that he always maintained since its initial work. Everybody remember him as a great person and a tireless scientist. Rest in peace Dr. Paul Ichiro Terasaki.


REFERENCES

  1. Terasaki PI. Scrapbook. Vol. I. Toppan Printing Company. Los Angeles, CA, USA. 2004.

  2. Terasaki PI. Tolerance of skin grafts produced by various adult cells, soluble extracts, and embryonic cells. J Embryol Exp Morphol. 1959; 7: 409-416.

  3. Terasaki PI, Mandell M, Vandewater J, Edgington TS. Human blood lymphocyte cytotoxicity reactions with allogenic antisera. Ann N Y Acad Sci. 1964; 120: 322-334.

  4. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature. 1964; 204: 998-1000.

  5. Starzl TE, Marchioro TL, Terasaki PI et al. Chronic survival after human renal homotransplantation. Lymphocyte-antigen matching, pathology and influence of thymectomy. Ann Surg. 1965; 162 (4): 749-787.

  6. Terasaki PI, Vredevoe DL, Mickey MR, et al. Serotyping for homotransplantation. VII. Selection of kidney donors for thirty-two recipients. Ann N Y Acad Sci. 1966; 129: 500-520.

  7. Terasaki PI. Resolution by HLA testing of 1,000 paternity cases not excluded by ABO testing. J Family Law. 1977; 16: 543-557.

  8. Terasaki PI, Gjertson D, Bernoco D, Perdue S, Mickey MR, Bond J. Twins with two different fathers identified by HLA. N Engl J Med. 1978; 299 (11): 590-592.

  9. Terasaki PI, Vredevoe DL, Mickey MR. Serotyping for homotransplantation. X. Survival of 196 grafted kidneys subsequent to typing. Transplantation. 1967; 5 (4) Suppl: 1057-1070.

  10. Patel R, Glassock R, Terasaki PI. Serotyping for homotransplantation. XIX. Experience with an interhospital scheme of cadaver-kidney sharing and tissue typing. JAMA. 1969; 207 (7): 1319-1324.

  11. Iwaki Y, Terasaki PI, Kinukawa T, Schulman B, Smith R. Trans-Pacific kidney shipment. Transplantation. 1983; 35 (5): 506-508.

  12. Ota K, Fuchinoue S, Nakamura M, Tokumoto T, Tanabe K, Toma H. Transplantation of kidneys donated from the USA: long-term results and viability testing using 31P-MRS. Transpl Int. 1997; 10 (1): 7-12.

  13. Collins GM, Bravo-Shugarman M, Terasaki PI, Braf Z, Sheil AG, Williams G. Kidney preservation for transportation. IV. Eight-thousand-mile international air transport. Aust N Z J Surg. 1970; 40 (2): 195-197.

  14. Wahlberg JA, Southard JH, Belzer FO. Development of a cold storage solution for pancreas preservation. Cryobiology. 1986; 23 (6): 477-482.

  15. McKenna RM1, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation. 2000; 69 (3): 319-326.

  16. Terasaki PI. Humoral theory of transplantation. Am J Transplant. 2003; 3 (6): 665-673.

  17. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant. 2004; 4 (3): 438-443.

  18. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant. 2007; 7 (2): 408-415.

  19. Russell TJ, Schultes LM, Kuban DJ. Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med. 1972; 287 (15): 738-740.

  20. White SH, Newcomer VD, Mickey MR, Terasaki PI. Disturbance of HL-A antigen frequency in Psoriasis. N Engl J Med. 1972; 287 (15): 740-743.

  21. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med. 1973; 288 (14): 704-706.

  22. Yonemoto RH, Terasaki PI. Cancer immunotherapy with HLA-compatible thoracic duct lymphocyte transplantation. A preliminary report. Cancer. 1972; 30 (6): 1438-1443.

  23. Deng C, Terasaki PI, El-Awar N, Billing R, Cicciarelli J, Lagasse L. Cytotoxic monoclonal antibody to a human leiomyosacoma. Lancet. 1981; 1 (8217): 403-405.

  24. Linker-Israeli M, Billing RJ, Foon KA, Terasaki PI. Monoclonal antibodies reactive with acute myelogenous leukemia cells. J Immunol. 1981; 127 (6): 2473-2477.

  25. Opelz G, Sengar DP, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc. 1973; 5 (1): 253-259.

  26. Park MS, Terasaki PI. Storage of human lymphocytes at room temperature. Transplantation. 1974; 18 (6): 520-524.

  27. Ozturk G, Terasaki PI. Non-HLA lymphocyte cytotoxins in various diseases. Tissue Antigens. 1979; 14 (1): 52-58.

  28. Cicciarelli JC, Chia D, Terasaki PI, Barnett EV, Shirahama S. IgM anti-IgM cold lymphocytotoxins to B cells. Transplant Proc. 1979; 11 (4): 1950-1953.

  29. Takahashi H, Terasaki PI, Iwaki Y, Nakata S. Identification of surface IgM as the target antigen of cold lymphocytotoxins. Tissue Antigens. 1980; 16 (2): 176-180.

  30. Foon KA, Fitchen JH, Billing RJ, Belzer MB, Terasaki PI, Cline MJ. An antithymocyte serum noncytotoxic to myeloid progenitor cells: candidate serum for prevention of graft-versus-host disease in bone marrow transplantation. Clin Immunol Immunopathol. 1980; 16 (4): 416-422.

  31. Trigg ME, Billing R, Sondel PM, et al. Depletion of T cells from human bone marrow with monoclonal antibody CT-2 and complement. J Biol Response Modifiers. 1984; 3: 406-412.

  32. Cicciarelli J, Terasaki PI, Cats S, Bogaars T, Hardiwidjaja S, Mendez R. Treatment of human kidney graft rejection episodes with monoclonal antibodies specific to mononuclear leukocytes. Transplantation Proc. 1985; 17: 1007-1008.

  33. Terasaki PI. Scrapbook. Vol. II. Colornet Press Printing. Los Angeles, CA, USA. 2015.

  34. Baranov A1, Gale RP, Guskova A, et al. Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med. 1989; 321 (4): 205-212.

  35. Pei R, Lee J, Chen T, Rojo S, Terasaki PI. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol. 1999; 60 (12): 1293-1302.

  36. Morales-Buenrostro LE, Terasaki P, Marino-Vázquez LLA, Lee JH, El-Awar N, Alberú J. “Natural” human leukocite antigen antibodies found in non-alloimmunized healthy males. Transplantation. 2008; 86 (8): 1111-1115.




2020     |     www.medigraphic.com